title: Consequences of acute myelogenous leukemia in early pregnancy.
abstract: Cytarabine and thioguanine therapy for acute myelomonocytic leukemia initiated in the tenth week of pregnancy (with the addition of vincristine and rubidomycin at 17 weeks) led to a short complete remission of the leukemia in a 24-year-old primigravida. This is the first case to be reported in which cytarabine was administered in the first trimester and a prostaglandin termination of pregnancy performed at 20 weeks produced an apparently normal fetus. A review of the literature suggests a slightly less than 50% chance of producing a live healthy baby if acute myelogenous leukemia is diagnosed in the first half of pregnancy, with materna mortality approaching 100% by six months postpartum. Current therapy may improve these figures.
mesh_terms: D000032:Abortion, Therapeutic; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy* / Q000401:mortality; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D012306:Risk; D013723:Teratogens; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013723:Teratogens; D003561:Cytarabine; D014750:Vincristine; D013866:Thioguanine; D003630:Daunorubicin